All In Biotech

Drug Trial Radar · NCT06349122

AUTOP 2: Screen-and-treat Strategy for Vaginal Flora Abnormalities by Molecular Biology in Pregnant Women at High Risk of Preterm Birth

Screen-and-treat Strategy for Vaginal Flora Abnormalities by Molecular Biology in Pregnant Women at High Risk of Preterm Birth: A Multicentre, Randomized Study (AUTOP 2)

Last checked: Nov 19, 2026Latest source record: Aug 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingPhase 3. Randomized with 1,794 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

1,794

Planned (sponsor's estimate)

Start

Oct 2026

Primary completion

Jun 2029

Study completion Jun 2029

Sponsor

Lead sponsor
Assistance Publique Hopitaux De MarseilleAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Apr 5, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Preterm birth is a major cause of mortality and long-term disability. Bacterial vaginosis (BV) is a frequent form of dysbiosis that is often asymptomatic and increases the risk of preterm birth. BV is usually diagnosed using conventional tools such as the Nugent score. Molecular diagnosis of BV has now been shown to be more reproducible and to provide a more accurate characterization of dysbiosis. The main objective of this study is to evaluate the effectiveness of a self screen and treat strategy for vaginal flora dysbiosis, based on molecular point of care (POC) multiplex technology before 18 weeks' gestation, in reducing the rate of preterm birth among pregnant women at high risk, compared with usual care. The hypothesis is that a Screen-and-Treat strategy using molecular biology among women with previous preterm or/and an history of late abortion could be effective in reducing preterm births by 40%.

Conditions

  • Bacterial Vaginosis
  • Vaginal Dysbiosis
  • Premature Delivery

Interventions

  • Vaginal flora abnormalities screening and quantification using molecular biology techniqueDiagnostic test

    Vaginal self-sampling is a simple and validated method of sampling used for the molecular biology technique and the quantification of microorganisms involved in vaginal flora imbalance bacteriosis.The patient performs a self-sampling with a cotton swab transferred into a transport medium tube. The sample is sent to the laboratory where Multiplex Point of Care polymerase chain reaction (PCR) is performed.

  • AzithromycinDrug

    In case of Chlamydia trachomatis infections: Azithromycin 1 g per os during the second and third trimester of pregnancy .

  • CeftriaxoneDrug

    In case of Neisseria gonorrhoeae infections: Ceftriaxone 1 g IM as a single dose.

  • MetronidazoleDrug

    In case of Trichomonas vaginalis infections: Metronidazole 500 mg 2 times/day for 7 days, whatever the trimester of pregnancy is . In case of Gardnerella vaginalis infection: Metronidazole 500 mg orally 2 times/day for 7 days . In case of Atopobium/Fannyhessea vaginae and/or Gardnerella vaginalis positivity: Metronidazole 500 mg orally 2 times/day for 7 days .

  • ClotrimazoleDrug

    In case of Candida albicans infection: 500 mg in a single dose. If necessary, this treatment could be repeated up to 6 times .

  • DoxycyclinDrug

    During first trimester of pregnancy ,in case of Chlamydia trachomatis infections at a dose of 200 mg/day 7 days .

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The rate of preterm birthTime frame: From the enrollment to the delivery date

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.